Follistim AQ is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):
FOLLISTIM AQ (follitropin alfa/beta - injectable; subcutaneous)
Manufacturer: ORGANON USA INC
Approval date: March 23, 2004
Strength(s): 300 IU/0.36ML [RLD], 600 IU/0.72ML [RLD]
Manufacturer: ORGANON USA INC
Approval date: February 11, 2005
Strength(s): 900 IU/1.08ML [RLD]
Manufacturer: ORGANON USA INC
Approval date: August 26, 2005
Strength(s): 150 IU/0.5ML [RLD], 75 IU/0.5ML [RLD]
Has a generic version of Follistim AQ been approved?
No. There is currently no therapeutically equivalent version of Follistim AQ available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Follistim AQ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
Patent 5,767,251
Issued: June 16, 1998
Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
Assignee(s): Genzyme Corporation
Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.Patent expiration dates:
- June 16, 2015✓
- June 16, 2015
Liquid gonadotropin containing formulations
Patent 5,929,028
Issued: July 27, 1999
Inventor(s): Skrabanja; Arnold Titus Philip & van den Oetelaar; Petrus Johannes Maria
Assignee(s): Akzo Nobel, N.V.
The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.Patent expiration dates:
- January 14, 2018✓✓
- January 14, 2018
FSH formulation
Patent 7,446,090
Issued: November 4, 2008
Inventor(s): Hoffmann; James Arthur & Lu; Jirong
Assignee(s): Ares Trading S.A.
This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.Patent expiration dates:
- August 23, 2019✓
- August 23, 2019
FSH and FSH variant formulations, products and methods
Patent 7,563,763
Issued: July 21, 2009
Inventor(s): Hoffmann; James Arthur & Lu; Jirong
Assignee(s): Ares Trading S.A.
This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.Patent expiration dates:
- August 23, 2019✓
- August 23, 2019✓
- August 23, 2019
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- June 28, 2013 - INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- August 22, 2014 - NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
See also...
- Follistim AQ Consumer Information (Drugs.com)
- Follistim AQ Consumer Information (Wolters Kluwer)
- Follistim AQ Consumer Information (Cerner Multum)
- Follistim AQ Advanced Consumer Information (Micromedex)
- Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
- Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
- Follitropin Beta Consumer Information (Wolters Kluwer)
- Follicle stimulating hormone Consumer Information (Cerner Multum)
- Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
- Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)
No comments:
Post a Comment